Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

Jun 11, 2014

Finding Answers for Rare Cancers

The rapid evolution of inexpensive genomic technologies is changing the way we approach rare malignancies.

Finding Answers for Rare Cancers

Moving from a histological to a molecular diagnostic approach to cancer is forcing us to reconsider the term “rare cancer.”

  • There is a genomic revolution upon us that is going to reshape the way we approach the treatment of rare cancers.

    One of the historical ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »